TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Pharmaxis Ltd ( (AU:SNT) ).
Pharmaxis Ltd has received guidance from the FDA regarding the clinical pathway for its drug amsulostat, which is being developed as a novel therapy for blood cancers such as myelofibrosis. The FDA has recommended conducting a Phase 2b study before proceeding to a Phase 3 trial, which will help define the safety and efficacy profile of amsulostat. This approach, while extending the timeline and increasing costs, reduces clinical risk and provides clarity on regulatory expectations, potentially attracting interest from partners. The company remains optimistic about amsulostat’s potential and its alignment with market needs, emphasizing that the drug’s long-term value remains intact despite recent share price volatility.
The most recent analyst rating on (AU:SNT) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Pharmaxis Ltd stock, see the AU:SNT Stock Forecast page.
More about Pharmaxis Ltd
Average Trading Volume: 7,312,273
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$44.07M
Find detailed analytics on SNT stock on TipRanks’ Stock Analysis page.